Difference between revisions of "Epithelioid sarcoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "'''contains protocol'''" to "'''contains dosing details in abstract'''") |
Warner-admin (talk | contribs) m (Text replacement - "'''contains dosing details in abstract'''" to "'''dosing details in abstract have been reviewed by our editors'''") |
||
| (18 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
[[#top|Back to Top]] | [[#top|Back to Top]] | ||
</div> | </div> | ||
| − | {{#lst: | + | {{#lst:Editorial board transclusions|sarcoma}} |
Note: these are regimens tested in subtype-specific populations, please see the '''[[Soft_tissue_sarcoma|main soft tissue sarcoma page]]''' for other regimens. | Note: these are regimens tested in subtype-specific populations, please see the '''[[Soft_tissue_sarcoma|main soft tissue sarcoma page]]''' for other regimens. | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
| Line 11: | Line 11: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| + | =Guidelines= | ||
| + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' | ||
| + | ==NCCN== | ||
| + | *''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1464 NCCN Guidelines - Soft Tissue Sarcoma].'' | ||
=All lines of therapy= | =All lines of therapy= | ||
==Tazemetostat monotherapy {{#subobject:a9367b|Regimen=1}}== | ==Tazemetostat monotherapy {{#subobject:a9367b|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:43c238|Variant=1}}=== | ===Regimen {{#subobject:43c238|Variant=1}}=== | ||
{| class="wikitable" style="color:white; background-color:#404040" | {| class="wikitable" style="color:white; background-color:#404040" | ||
| Line 21: | Line 25: | ||
{| class="wikitable" style="width: 60%; text-align:center;" | {| class="wikitable" style="width: 60%; text-align:center;" | ||
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
| − | !style="width: 33%"| | + | !style="width: 33%"|Dates of enrollment |
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://doi.org/10.1016/s1470-2045(20)30451-4 Gounder et al. 2020 (EZH-202)] | |[https://doi.org/10.1016/s1470-2045(20)30451-4 Gounder et al. 2020 (EZH-202)] | ||
| + | <!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26" | ||
| + | |'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-252-1 <span style="color:white;">ESMO-MCBS (1)</span>]''' | ||
| + | |- | ||
| + | |} --> | ||
|2015-2017 | |2015-2017 | ||
| style="background-color:#91cf61" |Phase 2 (RT) | | style="background-color:#91cf61" |Phase 2 (RT) | ||
|- | |- | ||
|} | |} | ||
| − | ====Biomarker | + | <div class="toccolours" style="background-color:#fdcdac"> |
| + | ====Biomarker eligibility criteria==== | ||
One or both of the following: | One or both of the following: | ||
*Loss of INI1 expression by IHC | *Loss of INI1 expression by IHC | ||
*Biallelic SMARCB1 alterations | *Biallelic SMARCB1 alterations | ||
| + | </div> | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
| − | *[[Tazemetostat (Tazverik)]] 800 mg PO twice per day | + | *[[Tazemetostat (Tazverik)]] 800 mg PO twice per day on days 1 to 28 |
'''28-day cycles''' | '''28-day cycles''' | ||
| + | </div></div> | ||
===References=== | ===References=== | ||
| − | <!-- # '''Abstract:''' Mrinal M. Gounder, Silvia Stacchiotti, Patrick Schöffski, Steven Attia, Antoine Italiano, Robin Jones, George D. Demetri, Stephen Blakemore, Alicia Clawson, Scott Daigle, Scott Ribich, Maria Roche, Jill Rodstrom, Peter T.C. Ho, and Gregory Michael Cote. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950). Journal of Clinical Oncology 2017 35:15_suppl, 11058-11058. [https://doi.org/10.1200/JCO.2017.35.15_suppl.11058 link to abstract] [https://clinicaltrials.gov/ | + | <!-- # '''Abstract:''' Mrinal M. Gounder, Silvia Stacchiotti, Patrick Schöffski, Steven Attia, Antoine Italiano, Robin Jones, George D. Demetri, Stephen Blakemore, Alicia Clawson, Scott Daigle, Scott Ribich, Maria Roche, Jill Rodstrom, Peter T.C. Ho, and Gregory Michael Cote. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma ([https://clinicaltrials.gov/study/NCT02601950 NCT02601950]). Journal of Clinical Oncology 2017 35:15_suppl, 11058-11058. [https://doi.org/10.1200/JCO.2017.35.15_suppl.11058 link to abstract] [https://clinicaltrials.gov/study/NCT02601950 NCT02601950] CT.gov] --> |
| − | # '''EZH-202:''' Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 Nov;21(11):1423-1432. | + | # '''EZH-202:''' Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 Nov;21(11):1423-1432. Epub 2020 Oct 6. [https://doi.org/10.1016/s1470-2045(20)30451-4 link to original article] '''dosing details in abstract have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/33035459/ PubMed] [https://clinicaltrials.gov/study/NCT02601950 NCT02601950] |
[[Category:Epithelioid sarcoma regimens]] | [[Category:Epithelioid sarcoma regimens]] | ||
Latest revision as of 23:40, 15 July 2024
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN, USA |
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
1 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Soft Tissue Sarcoma.
All lines of therapy
Tazemetostat monotherapy
Regimen
| FDA-recommended dose |
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Gounder et al. 2020 (EZH-202) | 2015-2017 | Phase 2 (RT) |
Biomarker eligibility criteria
One or both of the following:
- Loss of INI1 expression by IHC
- Biallelic SMARCB1 alterations
References
- EZH-202: Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 Nov;21(11):1423-1432. Epub 2020 Oct 6. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02601950